Publications by authors named "Rochelle Sun"
Background: There are limited data on the effectiveness of differentiated service delivery (DSD) for HIV care during sociopolitical turmoil. We assessed outcomes with a DSD model of care that includes patient choice between community-based antiretroviral therapy (ART) centres, home-based ART dispensing, or facility-based care at GHESKIO clinic during a period of severe civil unrest in Port-au-Prince, Haiti.
Methods: This retrospective analysis included data on patients with at least one HIV visit at GHESKIO between May 1, 2019, and December 31, 2021.
Article Synopsis
- A phase III clinical trial showed that omidubicel-onlv, a new cell therapy, leads to faster recovery for patients needing bone marrow transplants compared to standard treatments, benefiting all racial/ethnic groups.
- A decision-tree model projected effects of omidubicel-onlv use on health disparities in bone marrow transplants for over 10,000 eligible patients without matched donors, analyzing various usage scenarios.
- The findings indicated that higher omidubicel-onlv usage could significantly increase transplant rates and survival outcomes, especially for racial minorities, with notable improvements in access and reduced mortality rates.
The rising prevalence and associated public health burden of obesity has led to advancements in pharmaceuticals for weight management. Semaglutide 2.4 mg, an anti-obesity medication (AOM) recently approved by the US Food and Drug Administration, has demonstrated clinically relevant weight loss in its phase 3 clinical trials.
View Article and Find Full Text PDFBackground: Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults. The efficacy and safety of fremanezumab for migraine prevention have been demonstrated in randomized, double-blind, placebo-controlled trials. Real-world effectiveness data are needed to complement clinical trial data.
View Article and Find Full Text PDFBackground: The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of migraine in adults, have been demonstrated in randomized, double-blind, placebo-controlled trials. Real-world data can further support those clinical trial data and demonstrate the full clinical benefits of fremanezumab. This chart review assessed the effectiveness of fremanezumab for improving clinical outcomes in adult patients with migraine treated according to real-world clinical practice.
View Article and Find Full Text PDFWe compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.
View Article and Find Full Text PDFArticle Synopsis
- Rheumatoid arthritis (RA) is a long-term autoimmune disease, and Upadacitinib (UPA) is a new treatment option that is being compared to adalimumab (ADA) for its effectiveness and safety.
- The analysis used data from a specific clinical trial (SELECT-COMPARE) to assess how well UPA works compared to ADA and a placebo over time, focusing on how many patients achieve significant improvements and experience adverse events.
- Results showed that UPA was generally more effective than ADA in improving clinical outcomes over various time periods, with similar safety profiles except for a higher risk of herpes zoster with UPA.